Cue Biopharma Liabilities 2024

Cue Biopharma Aktienanalyse

What does Cue Biopharma do?

Cue Biopharma Inc is a biotechnology company focused on the development of novel immune-competent molecules for cancer therapy and immune system strengthening. The company was founded in 2016 and is headquartered in Cambridge, Massachusetts. The history of Cue Biopharma Inc began with the founding of the company by three leading scientists who combined their expertise in biology, chemistry, and drug design to develop novel and effective cancer immunotherapies. The company aimed to develop these new therapies with the precision of molecular interactions that are crucial for immune system control. Cue Biopharma Inc has a unique business model based on its proprietary CueMol technology platform, which enables the company to gain insightful understanding of molecular interactions in the immune system. By combining bioinformatics, artificial intelligence, and experimental technologies, CueMol is able to model the complex interplay of proteins, cells, and tissues in the immune system. The various divisions of Cue Biopharma Inc can be divided into three main areas: oncology, autoimmune diseases, and infectious diseases. In the field of oncology, the company has a pipeline of products including CB-010, CB-020, and CB-030, targeting different types of tumors. These therapeutics work by blocking protein-protein interactions that enable cancer cells to escape immune surveillance, thus improving the ability of the immune system to recognize and fight the tumor. In the field of autoimmune diseases, Cue Biopharma Inc has made significant progress in the development of CB-110, a therapeutic for the treatment of lupus. CB-110 works by regulating T cells, leading to a reduction in the inflammation that causes lupus symptoms. In the field of infectious diseases, Cue Biopharma Inc has played a valuable role in the development of COVID-19 therapeutics. In 2020, the company began developing CB-001, a drug targeting the SARS-CoV-2 virus. CueMol enabled the company to quickly understand the molecular interactions of the virus and develop CB-001 by disrupting these interactions. Cue Biopharma Inc has entered into several partnerships with leading pharmaceutical companies. In 2019, the company collaborated with Merck & Co. to further develop its CueMol platform and develop novel cancer immunotherapies. In 2020, the company worked with the Sheba Medical Center to test the efficacy of CB-001 in COVID-19 patients. Overall, Cue Biopharma Inc is a promising biotechnology company with the ability to develop novel immunotherapeutic drugs for the treatment of cancer, autoimmune diseases, and infectious diseases through the use of innovative technologies such as CueMol. With its partnerships, pipeline of therapeutics, and advanced technologies, Cue Biopharma Inc is poised to play a significant role in the biotechnology industry in the coming years. Cue Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Cue Biopharma's Liabilities

Cue Biopharma's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Cue Biopharma's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Cue Biopharma's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Cue Biopharma's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Cue Biopharma’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Cue Biopharma Stock

What is the level of liabilities of Cue Biopharma this year?

Cue Biopharma has a debt balance of 24.44 M USD this year.

What were the liabilities of Cue Biopharma compared to the previous year?

The liabilities of Cue Biopharma have increased by -4.51% dropped compared to the previous year.

What are the consequences of high debt for investors of Cue Biopharma?

High liabilities can pose a risk for investors of Cue Biopharma, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Cue Biopharma?

Low liabilities mean that Cue Biopharma has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Cue Biopharma affect the company?

An increase in liabilities of Cue Biopharma can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Cue Biopharma affect the company?

A decrease in the liabilities of Cue Biopharma can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Cue Biopharma?

Some factors that can influence the liabilities of Cue Biopharma include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Cue Biopharma so important for investors?

The liabilities of Cue Biopharma are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Cue Biopharma take to modify the liabilities?

To change its liabilities, Cue Biopharma can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Cue Biopharma pay?

Over the past 12 months, Cue Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cue Biopharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Cue Biopharma?

The current dividend yield of Cue Biopharma is .

When does Cue Biopharma pay dividends?

Cue Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cue Biopharma?

Cue Biopharma paid dividends every year for the past 0 years.

What is the dividend of Cue Biopharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cue Biopharma located?

Cue Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cue Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cue Biopharma from 4/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/28/2024.

When did Cue Biopharma pay the last dividend?

The last dividend was paid out on 4/28/2024.

What was the dividend of Cue Biopharma in the year 2023?

In the year 2023, Cue Biopharma distributed 0 USD as dividends.

In which currency does Cue Biopharma pay out the dividend?

The dividends of Cue Biopharma are distributed in USD.